Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $15.75

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $15.75.

Several equities analysts have recently commented on the stock. Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th. Oppenheimer lowered their price target on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, June 6th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research report on Thursday, June 13th. Finally, Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, March 13th.

Ventyx Biosciences Price Performance

VTYX opened at $2.31 on Tuesday. The stock’s 50 day simple moving average is $3.94 and its 200 day simple moving average is $4.13. The firm has a market cap of $162.86 million, a price-to-earnings ratio of -0.71 and a beta of 0.58. Ventyx Biosciences has a 1 year low of $1.87 and a 1 year high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. During the same quarter in the prior year, the business earned ($0.68) EPS. As a group, sell-side analysts anticipate that Ventyx Biosciences will post -2.31 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VTYX. China Universal Asset Management Co. Ltd. grew its stake in shares of Ventyx Biosciences by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the last quarter. Rafferty Asset Management LLC bought a new position in Ventyx Biosciences in the 3rd quarter worth about $209,000. Norden Group LLC purchased a new stake in Ventyx Biosciences during the 1st quarter valued at about $59,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ventyx Biosciences during the 1st quarter valued at about $72,000. Finally, SG Americas Securities LLC raised its holdings in Ventyx Biosciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 37,261 shares of the company’s stock worth $92,000 after buying an additional 14,177 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.